GC Genome Reports 7.44 Billion Won in Q1 Sales...Achieves First-Ever Quarterly Operating Profit

Sales Up 9.1%... Profitability Maintained for Four Consecutive Quarters
Balanced Growth in Obstetric, Cancer, and Rare Disease Testing
Core Product Sales Continue to Expand

GC Genome announced on May 15 that it recorded sales of 7.44 billion won and an operating profit of 140 million won in the first quarter of this year.

GC Genome Company Logo Image. GC Genome

Compared to the same period last year, sales increased by 9.1%, and both operating profit and net profit returned to the black. The company explained that, thanks to growth in major testing segments, it achieved its first-ever quarterly operating profit surplus. This marks the fourth consecutive quarter of profitability since the second quarter of last year.

By business segment, steady growth was seen across the major testing portfolio, including obstetric tests, cancer diagnostics, and rare disease tests. The non-invasive prenatal test (G-NIPT) contributed to sales growth through increased demand driven by a rising birth rate and an expanding client base.

The multi-cancer early screening test "iCanSearch" also continued to grow. The company stated that higher awareness of its tests and an increase in clients have contributed to improved performance.

A representative from GC Genome said, "We achieved our first-ever quarterly operating profit surplus based on the stable growth of our main testing portfolio and a profit-focused management strategy," adding, "We will continue our growth momentum through core growth products and new services."

This content was produced with the assistance of AI translation services.